NewtekOne, Inc. (NEWT)
Live price chart, market sentiment, and community perspectives for NewtekOne, Inc. (NASDAQ: NEWT).
Live price chart, market sentiment, and community perspectives for NewtekOne, Inc. (NASDAQ: NEWT).
On our desk, the narrative around NewtekOne centers on its strategic conversion to a financial holding company. Over the past 12 quarters, tangible book value has compounded substantially, climbing over 75%. While social media chatter earlier in the year noted insider buying by top executives indicating internal conviction, the recent Q2 2026 print showed a minor EPS miss relative to Wall Street consensus ($0.47 actual vs. ~$0.49 expected), causing shares to slide about 4%. Investors are weighing whether the impressive 50% asset growth against a minimal 3.6% expense increase outweighs near-term top-line predictability concerns.
Looking at the fundamental filings for Q2 2026, net income available to common shareholders climbed to $13.5 million with a diluted EPS of $0.47. Total assets ballooned to $3.18 billion, strongly supported by active loan growth and securitizations, with loans held for investment at amortized cost hitting $1.14 billion alongside $721.6 million in fair value loans. Deposits also scaled dramatically to $2.15 billion. However, standard profitability metrics like ROAA (1.97%), ROAE (13.3%), and ROTCE (15.7%) dipped relative to the prior year period. Risk managers should closely monitor how the bank funds this rapid balance sheet expansion given shifting macroeconomic guidance.
Watching the 50-day moving average and current consensus analyst targets around $15.33, NEWT presents an interesting valuation setup. The consensus rating currently sits at a Hold, split between a mix of sell, hold, and buy recommendations with a recent price near $12.83. For technical and fundamental evaluation, analysts should pay close attention to management's evolving guidance regarding the bank-centric model transition. Operating leverage is clearly working—evidenced by an efficiency ratio improving to 58.4%—but execution on deposit costs and loan yield spreads will dictate whether it hits the higher end of its projected ranges.
Explore plasma cleansing, somatic organ swaps, and BCI.